ctDNA

Today, much of cancer research begins with finding a target molecule that is important for a particular cancer and ends with a medicine—or “targeted agent”—that can exploit the target molecule in a way that causes death or impairment of cancer cells. That very specific interaction is often done with a monoclonal antibody, which is a very specific antibody ...